Literature DB >> 10755692

Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C.

Y Arase1, K Ikeda, K Chayama, N Murashima, A Tsubota, Y Suzuki, S Saitoh, M Kobayashi, M Kobayashi, F Suzuki, H Kumada.   

Abstract

The serum level of hepatitis C virus (HCV)-RNA is clinically important as a predictor of the response to interferon (IFN) therapy in patients with chronic hepatitis C. If serum HCV-RNA levels fluctuate during follow-up, and IFN therapy is begun at the time of a low HCV-RNA level, the IFN therapy may be more effective. We evaluated the fluctuation of HCV-RNA serum levels for 2 years in 212 patients with chronic hepatitis C, untreated with IFN who had HCV genotype 1b and an HCV-RNA level of 10 Meq/ml or more at first consultation. The HCV-RNA level was measured monthly for 2 years with an HCV branched DNA probe assay (b DNA probe assay). We classified HCV-RNA patterns into three types by the ratio of maximum HCV-RNA level (a) to minimum HCV-RNA level (b). In pattern 1 (constant type, 151 patients; 71.2%) the a/ b ratio was 1-5. In pattern 2 (slight fluctuation type, 46 patients; 21.7%) the a/b ratio was 5-10. In pattern 3 (severe fluctuation type, 15 patients; 7.1%), the a/b ratio was 10 or more. Next, we evaluated the factors associated with the three patterns. Acute exacerbation of chronic hepatitis was regarded as an increase in serum alanine aminotransferase (ALT) level to more than 250 IU/l. The incidence of acute exacerbation for a 2-year follow-up was 13.9% (21/151) in pattern 1, 19.6% (9/46) in pattern 2, and 53.3% (8/15) in pattern 3. Multivariate analysis showed that acute exacerbation was the most important factor in the manifestation pattern 3. In conclusion, we found that: (1) about 70% of patients had a constant HCV-RNA levels for 2 years. (2) A few patients had severe fluctuation of serum HCV-RNA level after acute exacerbation of chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755692     DOI: 10.1007/s005350050334

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  10 in total

Review 1.  Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection.

Authors:  C L Cooper; Curtis L Cooper; Paul MacPherson; William Cameron
Journal:  Can J Gastroenterol       Date:  2006-01       Impact factor: 3.522

2.  Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes.

Authors:  Catherine A Lázaro; Ming Chang; Weiliang Tang; Jean Campbell; Daniel G Sullivan; David R Gretch; Lawrence Corey; Robert W Coombs; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

4.  Comparison of serial Hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation.

Authors:  Howard B Gale; D Robert Dufour; Nazia N Qazi; Virginia L Kan
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

5.  Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles.

Authors:  Marco Hoffmann; Mirjam B Zeisel; Nikolaus Jilg; Glaucia Paranhos-Baccalà; Françoise Stoll-Keller; Takaji Wakita; Peter Hafkemeyer; Hubert E Blum; Heidi Barth; Philipp Henneke; Thomas F Baumert
Journal:  J Innate Immun       Date:  2009-06-23       Impact factor: 7.349

Review 6.  Hepatitis B virus and hepatitis C virus dual infection.

Authors:  Gaia Caccamo; Francesca Saffioti; Giovanni Raimondo
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

7.  Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis.

Authors:  John R Ticehurst; Fayez M Hamzeh; David L Thomas
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

Review 8.  Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review.

Authors:  Maurizio Pompili; Marco Biolato; Luca Miele; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

9.  Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Authors:  J R Peterson; F C Hsu; P A Simkin; M H Wener
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

10.  Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study.

Authors:  Ping Chen; Yang Zheng; Yubo Cai; Pengfei Zou; Nan Li; Conggao Peng; Hainv Gao; Jimin Liu; Yongping Chen; Zhaowei Tong; Lanjuan Li
Journal:  Can J Gastroenterol Hepatol       Date:  2020-04-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.